EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Aptose Biosciences's Enterprise Value is $10.86 Mil.
Aptose Biosciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-44.63 Mil. Therefore, Aptose Biosciences's EV-to-FCF for today is -0.24.
The historical rank and industry rank for Aptose Biosciences's EV-to-FCF or its related term are showing as below:
APTO'
s EV-to-FCF Range Over the Past 10 Years
Min: -3.72 Med: -0.6 Max: 0.48
Current: -0.25
During the past 13 years, the highest EV-to-FCF of Aptose Biosciences was 0.48. The lowest was -3.72. And the median was -0.60.
APTO's EV-to-FCF is ranked worse than 100% of 393
companies
in the Biotechnology industry
Industry Median: 4.27
vs APTO: -0.25
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for Aptose Biosciences's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Aptose Biosciences's EV-to-FCF
For the Biotechnology subindustry, Aptose Biosciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aptose Biosciences's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aptose Biosciences's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Aptose Biosciences's EV-to-FCF falls into.
Aptose Biosciences's current Enterprise Value is $10.86 Mil.
Aptose Biosciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-44.63 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Aptose Biosciences's PE Ratio for today is calculated as:
Aptose Biosciences's share price for today is $1.16.
Aptose Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.720.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Aptose Biosciences EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Aptose Biosciences's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Aptose Biosciences (Aptose Biosciences) Business Description
Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
APTO has been successfully added to your 